Your Health, We Care
In the pursuit of health and recovery, rational use of drugs is a crucial part. Patients should be fully aware of the information about the drug, including but not limited to efficacy, dosage, and contraindications, before using any drug. Be sure to follow the doctor's guidance and do not increase or decrease the dose or change the drug at will, so as not to affect the efficacy or cause adverse reactions; Be aware of drug-drug interactions and avoid self-medication.
Exkivity provides a new treatment option for NSCLC patients with EGFR exon 20 insertion mutations, with significant efficacy and a favorable safety profile.What diseases is Exkivit···【more】
Article source：Captain MedicineRelease date：2024-08-07Recommended：161
Capmatinib inhibits the proliferation and survival of MET-dependent cancer cells by inhibiting MET phosphorylation triggered by hepatocyte growth factor binding or MET amplificatio···【more】
Article source：Captain MedicineRelease date：2024-08-07Recommended：136
Exkivity is an innovative, oral, small molecule tyrosine kinase inhibitor (TKI) primarily for the treatment of adult patients with locally advanced or metastatic non-small cell lun···【more】
Article source：Captain MedicineRelease date：2024-08-07Recommended：155
Capmatinib is highly selective for c-Met targets, can effectively inhibit the proliferation and migration of c-Met-dependent tumor cells, and can effectively induce apoptosis to ac···【more】
Article source：Captain MedicineRelease date：2024-08-07Recommended：168
Capmatinib prevents the growth and spread of cancer cells by inhibiting MET tyrosine kinase activity. Usually this medication is indicated for those patients who do not respond to ···【more】
Article source：Captain MedicineRelease date：2024-08-06Recommended：209
Capmatinib is a targeted therapy for patients with non-small cell lung cancer with specific gene mutations, with significant efficacy and a relatively good safety profile.What is t···【more】
Article source：Captain MedicineRelease date：2024-08-06Recommended：232
Capmatinib is an oral drug manufactured by Novartis Pharmaceutical. It is a tyrosine kinase inhibitor that specifically targets the c-Met receptor. Capmatinib has shown durable eff···【more】
Article source：Captain MedicineRelease date：2024-08-06Recommended：204
Capmatinib inhibits the growth of cancer cells caused by specific genetic variants, i.e., MET exon 14 skipping or MET amplification. These genetic variants are common in tumors suc···【more】
Article source：Captain MedicineRelease date：2024-08-06Recommended：214
The price of Exkivity varies depending on a number of factors, including the version of the drug (innovator or generic), manufacturer, sales channel, and regional policies.Is Exkiv···【more】
Article source：Captain MedicineRelease date：2024-08-06Recommended：189
Exkivity is an orally targeted drug targeting EGFR gene mutations for the treatment of patients with non-small cell lung cancer who have not been treated with EGFR-targeted drugs a···【more】
Article source：Captain MedicineRelease date：2024-08-06Recommended：208
Exkivity is a targeted therapy for specific types of non-small cell lung cancer (NSCLC). Prices vary by region, sales channel, and version (innovator or generic).How much is a box ···【more】
Article source：Captain MedicineRelease date：2024-08-06Recommended：199
Exkivity is a targeted drug for the treatment of specific types of lung cancer, specifically developed for the treatment of patients with non-small cell lung cancer (NSCLC) harbori···【more】
Article source：Captain MedicineRelease date：2024-08-06Recommended：262
Lung cancer is the most rapidly increasing malignant tumor with the fastest increasing morbidity and···【more】
Recommended：3162024-09-07
On December 3, 2025, the U.S. Food and Drug Administration (FDA) granted full approval to pirtobruti···【more】
Recommended：92025-04-12
Primary analysis data from the randomized, double-blind, placebo-controlled phase III HER2CLIMB-02 s···【more】
Recommended：232025-01-12
The Cure SMA Foundation, a global leading non-profit organization dedicated to spinal muscular atrop···【more】
Recommended：242025-27-11
On November 14, 2024, the Committee for Medicinal Products for Human Use (CHMP) of the European Medi···【more】
Recommended：3052025-13-01
Recent advancements have reaffirmed the significance of liquid biopsy in the management of advanced ···【more】
Recommended：2682025-06-01
FDA Approves First Generic Version of Victoza (liraglutide injection)The U.S. Food and Drug Administ···【more】
Recommended：3492024-30-12
The new indication involves the treatment of adult patients with locally advanced, unresectable non-···【more】
Recommended：2492024-24-12
Lucius Pharmaceuticals (Lao) LTD. (Lucius Pharmaceuticals), with its manufacturing campus in Laos located in the capital city of Vientiane in 2020, officially begins its great journey to make effective and affordable medicines available to people in need around the world...More
Lucius Pharmaceutical Co., Ltd., was established in 2020 in Vientiane, the capital of Laos. It aims to offer safe, effective, and affordable medicines globally. With a factory spanning 25,000 square meters, the company manufactures 200+ generic drugs in diverse therapeutic fields.
Address:No.26 Thongmang village, Xaythany district, Vientiane Capital, Laos
E-mail:laoslucius@gmail.com
Whatsapp:
